China
Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood
LEO Pharma to acquire Replay gene therapy platform
The acquisition will advance innovation for patients with rare skin diseases
Almirall celebrates new offices in China to advance innovation in dermatology
The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners
Global Healthy Living Foundation and Medscape Education Join Forces to Bridge the Gap Between Patients and Providers with Immunology Education
UPPER NYACK, N.Y.--(BUSINESS WIRE)--The Global Healthy Living Foundation (GHLF) today announced a new partnership with Medscape Education to advance patient-centered innovation within the Immunology Learning Nexus (Nexus), Medscape’s flagship multi-year...
Almirall and Absci expand AI dermatological drug discovery partnership
The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target
Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study
The inflammatory skin condition affects over 26 million people in the US
Honoring the Legacy of Dr. Robert Sidbury, MD, MPH
We are deeply saddened by the recent passing of Dr. Robert Sidbury. Dr. Sidbury was a visionary in pediatric dermatology whose dedication to advancing patient care inspired clinicians, researchers, and...
LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront
Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis
Dermaliq and DEBRA partner to advance epidermolysis bullosa drug delivery
Approximately 500,000 people worldwide are affected by the rare genetic skin disorders
LEO Pharma and the Parker Institute join forces to advance dermatology research
The alliance will aim to discover molecules that could be incorporated into wider pharmaceutical research
LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe
Approximately 125 million people worldwide are affected by some form of the inflammatory condition
AstraZeneca announces $2.5bn investment in China to boost R&D capabilities
The funds will go towards a new global research and development centre in Beijing’s BioPark